PRZOOM - /newswire/ -
Poway, CA, United States, 2017/08/25 - ProSci Incorporated, a San Diego-based privately held biotechnology firm, has announced the addition of flow cytometry to the list of antibody screening services offered for custom monoclonal antibody services - ProSci-Inc.com.
Flow cytometry screening will be offered for the following monoclonal antibody development services: mouse hybridoma development, rabbit monoclonal antibody, and single domain antibody.
“Our priority at ProSci Incorporated is to provide the highest quality monoclonal, polyclonal, and single domain antibody services in the industry,” says, David Eling, Ph.D. Director of Business Development,“We saw a need for scientists and researchers developing flow antibodies in our industry, and decided to incorporate flow cytometry into our current screening service offering for monoclonal antibody development.”
The flow cytometry screening service will include screening up to two cell line for positively expressed protein targets of interest throughout each phase of development. Additional cell line screening can also be performed at added cost.
The addition of flow cytometry to ProSci’s offerings will increase the value of the services to scientists, researchers, and other technologists. Since many antibody manufacturers only have Western blot and ELISA screening capabilities, relying on outsourcing to test their antibodies in flow independently.
To learn more about flow cytometry screening, visit ProSci's website.
About ProSci Incorporated
ProSci Incorporated (prosci-inc.com) is a privately-held biotechnology firm located in San Diego, California. A leader in its field, ProSci’s priority is to provide the highest quality monoclonal, polyclonal, and single domain antibody services in the industry. ProSci’s expertise in antibody production, immunochemistry services, and biological research is realized through customizable services, innovative products, competitive pricing, high-quality research tools, and unparalleled technical support.